Dr Patrick Bowden

Radiation Oncologist
Become a Patient

Dr Patrick Bowden is committed to providing comprehensive, patient-centred cancer care. He is a highly experienced doctor who remains at the forefront of cutting-edge radiation therapy techniques and clinical research.


Dr Patrick Bowden has 20 years’ experience as a consultant radiation oncologist and is based at Icon Cancer Centre Richmond, Freemasons, Moreland, Mulgrave and Canberra. He has continually been at the forefront of new technologies in radiation therapy treatment throughout his oncology career. Dr Bowden is a leading specialist in the use of intensity modulated radiation therapy [IMRT] and stereotactic radiation therapy for treatment of early metastatic disease.

After establishing his radiation oncology career at Peter MacCallum Cancer Centre, he became director of the Tattersall’s Cancer Centre in 2007, the private arm of Peter MacCallum Cancer Centre. In 2011 he was appointed as the inaugural Director of Epworth Radiation Oncology. In this role he built Australia’s largest stereotactic radiation therapy service including a clinical trial institute and integrated oncology services at Epworth Freemasons. In 2016 the South West Regional Cancer Centre in Warrnambool was established under his directorship before his integral role in the transition of Epworth Radiation Oncology to Icon Cancer Centre.

Dr Bowden is actively involved in education, medical leadership, research and clinical trials. He was previously a member of Epworth Medical Advisory Committee from 2007-2016 (maximum allowed 9-year tenure). Outside radiation oncology, he is the Chairman of Access Telehealth; Australia’s largest provider of free consultations to patients in rural and remote areas.

Dr Bowden has been active in numerous clinical trials and acted as principal investigator in key studies investigating radiation therapy treatments for lung, cervix and prostate cancers. In July 2019, his world-leading study TRANSFORM was published in the International Journal of Cancer, evaluating the efficacy of stereotactic radiation therapy for oligometastatic prostate cancer. In June 2021, his PINPOINT study investigating the use of Calypso guidance beacons to reduce prostate radiation therapy side effects was published in the World Journal of Urology. Both Australian studies with the support of Epworth Medical Foundation and EJ Whitten Foundation were the world’s largest clinical trials of their kind.

His clinical experience covers a broad range of solid tumour malignancies, with a special interest in urological cancers (including prostate cancer), gastrointestinal cancer, central nervous system (CNS) and metastatic cancers.

Affiliations & Memberships

  • Royal Australian and New Zealand College of Radiologists (RANZCR)

Special Interests

Dr Patrick Bowden accepts referrals for all cancer types, with a special clinical interest in:
  • Brain and spine (CNS) cancer
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Oligometastatic disease
  • Prostate cancer

Icon Locations

Epworth Richmond View centre
Epworth Freemasons View centre
Moreland View centre
Canberra View centre
Mulgrave View centre
Holmesglen View centre

Visiting Locations

  • Malvern
  • Lilydale
  • Epworth Eastern
  • Box Hill


  • Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. Patrick Bowden, Andrew W. See, Kevin So, Nathan Lawrentschuk, Daniel Moon, Declan G. Murphy, Ranjit Rao, Alan Crosthwaite, Dennis King, Hodo Haxhimolla, Jeremy Grummet, Paul Ruljancich, Dennis Gyomber, Adam Landau, Nicholas Campbell, Mark Frydenberg, Lloyd M. L. Smyth, Skye Nolan, Stella M. Gwini & Dean P. McKenzie. World Journal of Urology, June 2021.

  • Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Patrick Bowden, Andrew W. See, Mark Frydenberg, Hodo Haxhimolla, Anthony J. Costello, Daniel Moon, Paul Ruljancich, Jeremy Grummet, Alan Crosthwaite, Ganes Pranavan, Justin S. Peters, Kevin So, Stella M. Gwini, Dean P. McKenzie, Skye Nolan, Lloyd M.L. Smyth, Craig Everitt. International Journal of Cancer, June 2019.

  • Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after failed primary treatment. Fairleigh Reeves, Declan Murphy, Christopher Evans, Anthony J. Costello, Patrick Bowden. BJU International, 2014; 116. 10.1111/bju.12957.

  • Prostate cancer multidisciplinary care: improving patient outcomes. Phil Dundee, Lih-Ming Wong, Niall Corcoran, Addie Wootten, Helen Crowe, David Sandall, Adam Dowrick, Patrick Bowden, Ben Tran, Jane Crowe, Richard O’Sullivan, Andrew Ryan, Anthony J. Costello. Trends in Urology & Mens Health, 2015; 6. 10.1002/tre.468.

  • The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Brindha Pillay, Addie Wootten, Helen Crowe, Niall Corcoran, Ben Tran, Patrick Bowden, Jane Crowe, Anthony J. Costello. Cancer Treatment Reviews. 2015; 42. 10.1016/j.ctrv.2015.11.007.

  • 223PUsing PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy. Angelyn Anton, Z. Ballok, Patrick Bowden, T. Costello, L. Harewood, Niall Corcoran, Phil Dundee, J. Peters, N. Lawrentschuk, Andrew Troy, D. Webb, Y. Chan, Andrew See, Shankar Siva, Declan Murphy, Michael Hoffman, Ben Tran. Annals of Oncology, 2018; 29. 0.1093/annonc/mdy434.011.